Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain.
about
Conjugate vaccines for preventing meningococcal C meningitis and septicaemiaConjugate vaccines for preventing meningococcal C meningitis and septicaemiaImmunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal c conjugate vaccineCost-effectiveness of alternate strategies for childhood immunization against meningococcal disease with monovalent and quadrivalent conjugate vaccines in Canada.Optimizing strategies for meningococcal C disease vaccination in Valencia (Spain).Early appearance of bactericidal antibodies after polysaccharide challenge of toddlers primed with a group C meningococcal conjugate vaccine: what is its role in the maintenance of protection?Effectiveness of meningococcal C conjugate vaccine in Salvador, Brazil: a case-control study.Meningococcal conjugate vaccines: optimizing global impact.Meningococcal disease serogroup C.Immunization strategies for the control of serogroup C meningococcal disease in developed countries.Experience with MCV-4, a meningococcal, diphtheria toxoid conjugate vaccine against serogroups A, C, Y and W-135.A surveillance network for meningococcal disease in Europe.Long-term protection in children with meningococcal C conjugate vaccination: lessons learned.Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2-10-year-old children: results of an open, randomised, controlled study.Routinely vaccinating adolescents against meningococcus: targeting transmission & diseaseA randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2-10 years.Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlersMeningococcal serogroup A, C, W₁₃₅ and Y conjugated vaccine: a cost-effectiveness analysis in the NetherlandsImpact of vaccination on meningococcal epidemiologyNeonatal and infantile immune responses to encapsulated bacteria and conjugate vaccines.Reduction in Neisseria meningitidis infection in Italy after Meningococcal C conjugate vaccine introduction: A time trend analysis of 1994-2012 series.Prevention of meningococcal serogroup C disease by NeisVac-C.Vaccination against meningitis B: is it worth it?Cost-effectiveness of vaccination against meningococcal B among Dutch infants: Crucial impact of changes in incidence.Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs.Evaluation of the impact of serogroup C meningococcal disease vaccination program in Brazil and its regions: a population-based study, 2001-2013New frontiers in meningococcal vaccines.Epidemiology and prevention of meningococcal disease: a critical appraisal of vaccine policies.Advances with vaccination against Neisseria meningitidis.Meningococcal vaccines: current issues and future strategies.Glycoconjugate vaccines: an update.Conjugate Meningococcal Vaccines Development: GSK Biologicals Experience.Update on the use of meningococcal serogroup C CRM₁₉₇-conjugate vaccine (Meningitec) against meningitis.Fighting Neisseria meningitidis: past and current vaccination strategies.Effect of increased CRM₁₉₇ carrier protein dose on meningococcal C bactericidal antibody response.Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination.Quality of the Haemophilus influenzae type b (Hib) antibody response induced by diphtheria-tetanus-acellular pertussis/Hib combination vaccines.Impact of Meningococcal C Conjugate Vaccination Programs with and without catch-up campaigns in adolescents: lessons learned from Bahia, Brazil.Vaccination strategies for the prevention of meningococcal disease.
P2860
Q24235722-A12C5D07-1A73-4E48-9084-5ED29D90DE14Q24244951-6225A65B-E3B3-4355-BB8B-DD331F1DF50DQ28749695-6308431E-54F9-482D-86A0-A08749457833Q33637512-0398BDA3-8957-4B28-A89D-127953C1C016Q33799111-8B83D3BB-D463-4648-A823-8B85135F81C2Q34975007-505370EB-16AD-402C-B1C4-7D9DC5E0D2BFQ35390370-0EAD697E-44B6-4C69-91A6-1BE5E6CC85B7Q35547767-270767CE-096E-4F7C-B104-F8CA76716A51Q35832179-7C76F1E5-492E-415E-8C3D-6337B1A7A68CQ36445558-96D2F469-7908-4FA1-990B-7FDBB7158425Q36600323-B31299C9-28A2-4AA9-850C-32AA8C69E74EQ36683965-F7E3C3FA-8059-433A-86AE-1E5864F0F2D1Q36690297-3E502512-F486-4A43-81EC-DFFAE2C98B40Q36781534-7D0E68EC-2C08-475A-920B-2A7CD3C2E71FQ36825737-292C0029-F232-46AE-A421-0EAF107D92B3Q36849830-11132285-FEDE-4CF4-AC0F-1739E70A8870Q36849834-8C8EB797-D60C-404F-81BC-AD68D4A6DEBFQ36891586-DE918201-4ED0-45E3-A9CF-BF6D239B8973Q37130791-72C3CE3D-693A-49DC-A3B7-365909F60529Q37282316-F0C96923-AC1D-4D0A-B940-A185F8F1C579Q37309285-38F53C8E-ABEA-4CDB-B76B-5DD744EBFA46Q37403478-7F5EFE48-F650-48A6-ACB5-E5877918E6EFQ37449169-9ED9B7D2-09D4-4DBD-9D6F-72CE061B4D7FQ37505414-C22B21ED-BA8B-43DD-BA1C-98B89C1D6446Q37524027-9EF58108-8DED-424F-BC92-98CD2F195F1CQ37705727-C43030CB-2E9F-414A-A1D3-569FE34442DBQ37878480-9FFA47EC-A433-4570-985B-496C79C061C0Q37956384-7BF9F4EA-7235-4DE4-B243-4978B58E5CECQ38040527-8352505A-CB3D-4E08-816C-47C60A169C30Q38120493-AD712112-E5F3-440F-84FB-5F8CCA19DB07Q38286346-13041B31-0FD6-46C4-9555-71E9F1007A9EQ38367830-31DB594B-FD3E-46F2-9D28-887B82D187D0Q38631381-0251C2A0-1FE4-4B2F-959F-166933C73F2BQ38829564-B2D9CF06-4471-4819-9DEE-9343FFC1FA31Q41812746-8E1905E9-2ABB-433C-BA8F-EA2D9342A585Q42255158-30F18B29-D647-4540-BC4D-3ED837A18899Q42909238-5FAD1CDC-155E-4182-BD41-B47E9C8B2CFBQ47301746-3FEDC73F-7095-44FE-B775-DAD4A26EB83CQ54964676-E211B82D-8E2B-4AD7-90F0-564CE79F48F7
P2860
Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Impact and effectiveness of me ...... ing its introduction in Spain.
@en
Impact and effectiveness of me ...... ing its introduction in Spain.
@nl
type
label
Impact and effectiveness of me ...... ing its introduction in Spain.
@en
Impact and effectiveness of me ...... ing its introduction in Spain.
@nl
prefLabel
Impact and effectiveness of me ...... ing its introduction in Spain.
@en
Impact and effectiveness of me ...... ing its introduction in Spain.
@nl
P2093
P1433
P1476
Impact and effectiveness of me ...... ing its introduction in Spain.
@en
P2093
Martina García
Salvador de Mateo
P304
P356
10.1016/J.VACCINE.2005.03.045
P407
P577
2005-07-01T00:00:00Z